Patheon Inc

Patheon — UBS Global Life Sciences Conference 2005

20 slides from Patheon's conference presentation, Sep 27, 2005

  1. Slide 1: UBS Global Life Sciences Conference

    UBS Global Life Sciences Conference September 27, 2005 1 Forward-looking Information This presentation contains forward-looking statements with respect to the Company, including its business operations and strategy and financial performance and condition. Although management believes that the expect

  2. Slide 2: Today's Presentation

    Today’s Presentation ƒ Company overview ƒ Target markets and business strategy ƒ Recent strategic achievements ƒ YTD 2005 financial results ƒ Outlook 3 COMPANY OVERVIEW 4 UBS Life Sciences, Sept 27, 2005 2

  3. Slide 3: Patheon Today

    Patheon Today 180+ clients 750+ products sold in 120+ countries 137 PDS projects under development (1) 14 sites in North America and Europe 5,900 employees US$470.3M 2004 revenues (US$516.4 YTD ‘05) ~US$670M market cap (2) 39% 10-year revenue CAGR 22% 10-year EPS CAGR (3) (1) As at third quarter end

  4. Slide 4: Growing Global Pharma Market / Our Target Markets

    Growing Global Pharma Market Global Pharma Market: $550 billion (1) Global Market U.S. Market ~7-10% (2) ~ 8% (3) (1) IMS Reports 2004 Global Pharmaceutical Sales Grew 7 Percent to $550 Billion, IMS Health, March 9, 2005 7 (2) IMS Reports 8.3 Percent Dollar Growth in 2004 U.S. Prescription Sales, IM

  5. Slide 5: Our Vision / Focused Business Strategy

    Our Vision To be the world leader in pharmaceutical product manufacturing. 9 Focused Business Strategy ƒ Focused on meeting the needs of global pharma, pharma, specialty pharma and biotech clients for finished dosage form development and manufacturing services • not an API manufacturer or CRO • do n

  6. Slide 6: Our Services / Global Manufacturing Network

    Our Services Commercial Preformulation Manufacturing Clinical Trial Manufacturing Drug Development Sales and Discovery and Manufacturing Distribution Formulation Development Analytical Scale-Up Development 11 Global Manufacturing Network Toronto (Canada) Swindon (UK) 6 Canadian Sites Monza (Italy) F

  7. Slide 7: International PDS Locations / More than 180 clients

    International PDS Locations Four Centers of Excellence • Conventional • Conventional dosage • Conventional dosage • Lyophilized products dosage forms forms forms • Peptides/Proteins •Specialized solid •Steriles • 0.2m2 , 0.4m2, and • Low-solubility 0.8m2 development lyo dosage forms compounds •Pepti

  8. Slide 8: Improving the Quality of Revenues

    Improving the Quality of Revenues Approval Patent Expires Phase III Phase II Phase I Patent filing NDA Mature Increasing Volumes, Revenues NME Declining Volumes, Revenues Development Launch Commercialization Patheon PDS Patheon commercial manufacturing 15 NME = New Molecular Entity PDS Projects Show

  9. Slide 9: 100 Great Investigational Drugs / PDS Project Launches

    100 Great Investigational Drugs ƒ Patheon is currently developing nine of the “100 Great Investigational Drugs”1 for its clients. 17 (1) R&D Directions, Neal Bellucci, March 2005 Thirteen PDS Project Launches 2001 July 2005 Approved PDS Commercialization 7 new launches in 2004 and YTD 2005 18 UBS Li

  10. Slide 10: Thirteen PDS Project Launches: The Novartis Comparison

    Thirteen PDS Project Launches: Three in the Top 200 selling Rx Drugs 2001 July 2005 Approved PDS Commercialization Each of the Top 200 Rx Drugs generates global retail sales of $396 million or more1. 19 (1)Based on MedAd News, Top 500 Prescription Drugs, May 2005 The Novartis Comparison Phase I Phas

  11. Slide 11: Our Growth Strategy

    Patheon Manufactures 19 of Top 200 Rx drugs Each generating global retail sales of $396 million or more(5) 19 Developed in 3 Patheon PDS 3 3 16 10 10 13 1 (3) (4) (5) 2000 (1) 2002 (2) 2003 2004 2005 (1) PharmaBusiness, The Pharma 500, May 1999. (2) PharmaBusiness, The Pharma 200, May 2002. 21 (3) M

  12. Slide 12: Our Growth Strategy

    Our Growth Strategy Repeat Business Internal Transfer from PDS New Clients Product Carve- Carve-Outs Site Acquisitions Strategic Acquisition of Competitors 23 2005 2004 NEW ERA Four more Addition of MOVA PDS projects approved, RAPID bringing total GROWTH 2002 to 10 since Added first 2001 AND U.S. si

  13. Slide 13: Shift Towards Higher-Margin Revenues

    Shift Towards Higher-Margin Revenues YTD 2005 (as % total revenues) PDS Rx 14% 12% OTC 65% 72% 21% 16% YTD '04 YTD' 05 ƒ PDS and Rx represent 84% of revenues vs. 79% a year ago ƒ Reflects strong internal growth and addition of strategic revenues (all Rx) from MOVA 25 Revenues by Geographic Region YT

  14. Slide 14: Recent Strategic Accomplishments and Financial Results

    RECENT STRATEGIC ACCOMPLISHMENTS AND FINANCIAL RESULTS 27 Recent Strategic Accomplishments ƒ Completed acquisition of MOVA Pharmaceutical Corporation (December 2004) ƒ Swindon repositioning on track: EBITDA- EBITDA-positive in Q2 ‘05 ƒ Launched 13 PDS products since 2001 for which Patheon has been s

  15. Slide 15: Revenue Growth

    Revenue Growth YTD 2005 $516.4M $347.4M 49% YTD '04 YTD '05 ƒ Internal growth of 17% YTD ƒ Rx up 18% overall ƒ PDS up 30% ƒ MOVA contribution of $108.4M 29 Revenue Growth YTD 2005 ƒ North American revenues grew 68% ($147.8M) ƒ NA internal growth was 18% YTD, reflecting strong growth in Rx manufactur

  16. Slide 16: EBITDA and EBITDA Margin

    EBITDA and EBITDA Margin YTD 2005 ƒ EBITDA up 107% to $71.8M ƒ EBITDA margin of 13.9% vs. 10.6%* ƒ Increased Rx volumes in both NA and Europe ƒ Growth in PDS ƒ Improved product mix in both NA and Europe ƒ Significant improvement in operating performance at Swindon, Ferentino and Toronto sites *Befor

  17. Slide 17: Net Earnings and EPS / Cash Flow & Liquidity

    Net Earnings and EPS YTD 2005 $13.2 $7.7 72% YTD '04 YTD '05 ƒ Net earnings of $13.2M vs. $7.7M* a year ago ƒ EPS of 15.6 cents vs. 14.9 cents a year ago ƒ MOVA not accretive YTD ƒ Reflects 65% increase YOY in the average number of shares outstanding in the quarter relating to the MOVA acquisition 3

  18. Slide 18: Outlook

    OUTLOOK 35 Outlook ƒ Demand for PDS services remains strong in NA and Europe • Driven by: • R&D spending; • Biotech financing availability • Increased demand for high-quality services ƒ Growing demand for specialized Rx manufacturing services • NA: high-potency and sustained release • Europe: steril

  19. Slide 19: Outlook / The Future

    Outlook MOVA: • API supply for major product returning to normal • Production levels of newly launched product returning to market demand following trade inventory correction • Challenge is to secure new business to offset declining volumes of product going off patent later in 2006 and other volume

  20. Slide 20: The Future: Pharmaceutical Sector Trends

    The Future: Pharmaceutical Sector Trends “Big Pharma’s quest for finding innovative drugs will soon take a backseat to operating efficiency. Merck, like all the big drug makers, is going to need to become more financially efficient in order to restore itself to its former profitability and maintain

Patheon — UBS Global Life Sciences Conference 2005 on 6ix